300463 迈克生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.544-0.5671.9884.93213.372
总资产报酬率 ROA (%)0.433-0.4491.5763.8399.612
投入资产回报率 ROIC (%)0.460-0.4851.7214.25910.866

边际利润分析
销售毛利率 (%)57.28758.97055.11255.26954.224
营业利润率 (%)1.542-2.7996.66911.43522.652
息税前利润/营业总收入 (%)3.510-3.6835.53511.35022.375
净利润/营业总收入 (%)2.864-1.9124.66010.52219.446

收益指标分析
经营活动净收益/利润总额(%)151.218-11.562182.347127.450107.082
价值变动净收益/利润总额(%)3.06712.3464.0330.4960.385
营业外收支净额/利润总额(%)6.52738.958-36.353-8.441-3.588

偿债能力分析
流动比率 (X)3.9933.0643.0433.7684.336
速动比率 (X)2.9122.2582.2892.9583.377
资产负债率 (%)18.98821.12619.46618.57120.065
带息债务/全部投入资本 (%)13.80214.09810.95910.51010.026
股东权益/带息债务 (%)613.887598.458791.034822.557860.515
股东权益/负债合计 (%)424.932371.579410.207423.457383.964
利息保障倍数 (X)1.887-4.0768.58514.10044.145

营运能力分析
应收账款周转天数 (天)190.790224.023235.631239.125197.322
存货周转天数 (天)345.258353.858284.620270.555230.579